**SUPPLEMENTAL DIGITAL CONTENT**

**List of Supplemental Digital Content:**

Supplemental Digital Content 1.docx

*Search terms used to identify relevant articles*

Supplemental Digital Content 2.docx

*Table S2. Incidence of low birth weight and prematurity in pregnancy after transplantation*

Supplemental Digital Content 3.docx

*Table S3****.*** *Case reports: pregnancy outcomes in women on MPA treatment*

**Supplemental Digital Content 1.** Search terms used to identify relevant articles

Embase:

('tacrolimus'/de OR 'mycophenolic acid'/de OR 'mycophenolate mofetil'/de OR (tacrolim\* OR prograft\* OR mycophenol\* OR FK-506 OR FK506 OR FR-900506 OR FR900506 OR cellcept OR myfortic OR RS-61443 OR RS61443):ab,ti) AND ('pregnant woman'/de OR 'lactation'/de OR 'pregnancy outcome'/de OR 'embryo'/de OR 'fetus'/de OR 'pregnancy'/exp OR 'fertility'/exp OR 'teratogenicity'/de OR 'pregnancy disorder'/exp OR 'birth'/exp OR (neonat\* OR newborn\* OR new-born\* OR childbirth\* OR stillbirth\* OR birth\* OR parturition\* OR transplacental\* OR placenta\* OR abortion\* OR teratogenicit\* OR teratogeneit\* OR lactat\* OR lactic\* OR eclamp\* OR preeclamp\* OR pre-eclamp\* OR embryo OR embryopath\* OR fecundit\* OR sperm-ovum\* OR fertilit\* OR pregnant\* OR pregnanc\* OR feto OR fetomaternal\* OR fetus\* OR foetus\* OR fetal OR fetalmaternal\* OR foetal\* OR childbear\* OR gestat\* OR gravid\* OR labor OR labour OR ((child\*) NEAR/3 (bear\*)) OR ((breast\* OR mamma\* OR milk\*) NEAR/3 (secret\* OR excret\* OR releas\*))):ab,ti) AND ('transplantation'/exp OR (transplant\* OR allograft\* OR allotransplant\* OR autograft\* OR autotransplant\* OR graft\* OR isograft\* OR isotransplant\* OR retransplant\* OR xenograft\* OR xenotransplant\* OR inplant OR implant OR homograft\* OR homotransplant\*):ab,ti) NOT ([animals]/lim NOT [humans]/lim) AND [english]/lim NOT ([Conference Abstract]/lim)

Medline:

(Tacrolimus/ OR Mycophenolic Acid/ OR (tacrolim\* OR prograft\* OR mycophenol\* OR FK-506 OR FK506 OR FR-900506 OR FR900506 OR cellcept OR myfortic OR RS-61443 OR RS61443).ab,ti.) AND (Pregnant Women/ OR Lactation/ OR exp Pregnancy Outcome/ OR exp Fetus/ OR exp Pregnancy/ OR exp Fertility/ OR Teratogenesis/ OR exp Pregnancy Complications/ OR exp Parturition/ OR (neonat\* OR newborn\* OR new-born\* OR childbirth\* OR stillbirth\* OR birth\* OR parturition\* OR transplacental\* OR placenta\* OR abortion\* OR teratogenicit\* OR teratogeneit\* OR lactat\* OR lactic\* OR eclamp\* OR preeclamp\* OR pre-eclamp\* OR embryo OR embryopath\* OR fecundit\* OR sperm-ovum\* OR fertilit\* OR pregnant\* OR pregnanc\* OR feto OR fetomaternal\* OR fetus\* OR foetus\* OR fetal OR fetalmaternal\* OR foetal\* OR childbear\* OR gestat\* OR gravid\* OR labor OR labour OR ((child\*) ADJ3 (bear\*)) OR ((breast\* OR mamma\* OR milk\*) ADJ3 (secret\* OR excret\* OR releas\*))).ab,ti.) AND (exp Transplantation/ OR (transplant\* OR allograft\* OR allotransplant\* OR autograft\* OR autotransplant\* OR graft\* OR isograft\* OR isotransplant\* OR retransplant\* OR xenograft\* OR xenotransplant\* OR inplant OR implant OR homograft\* OR homotransplant\*).ab,ti.) NOT (exp animals/ NOT humans/) AND english.la. NOT (news OR congres\* OR abstract\* OR book\* OR chapter\* OR dissertation abstract\*).pt.

Cochrane (RCTs):

((tacrolim\* OR prograft\* OR mycophenol\* OR (FK NEXT/1 506) OR FK506 OR (FR NEXT/1 900506) OR FR900506 OR cellcept OR myfortic OR (RS NEXT/1 61443) OR RS61443):ab,ti) AND ((neonat\* OR newborn\* OR (new NEXT/1 born\*) OR childbirth\* OR stillbirth\* OR birth\* OR parturition\* OR transplacental\* OR placenta\* OR abortion\* OR teratogenicit\* OR teratogeneit\* OR lactat\* OR lactic\* OR eclamp\* OR preeclamp\* OR (pre NEXT/1 eclamp\*) OR embryo OR embryopath\* OR fecundit\* OR (sperm NEXT/1 ovum\*) OR fertilit\* OR pregnant\* OR pregnanc\* OR feto OR fetomaternal\* OR fetus\* OR foetus\* OR fetal OR fetalmaternal\* OR foetal\* OR childbear\* OR gestat\* OR gravid\* OR labor OR labour OR ((child\*) NEAR/3 (bear\*)) OR ((breast\* OR mamma\* OR milk\*) NEAR/3 (secret\* OR excret\* OR releas\*))):ab,ti) AND ((transplant\* OR allograft\* OR allotransplant\* OR autograft\* OR autotransplant\* OR graft\* OR isograft\* OR isotransplant\* OR retransplant\* OR xenograft\* OR xenotransplant\* OR inplant OR implant OR homograft\* OR homotransplant\*):ab,ti)

Web of Science:

TS=(((tacrolim\* OR prograft\* OR mycophenol\* OR FK-506 OR FK506 OR FR-900506 OR FR900506 OR cellcept OR myfortic OR RS-61443 OR RS61443)) AND ((neonat\* OR newborn\* OR new-born\* OR childbirth\* OR stillbirth\* OR birth\* OR parturition\* OR transplacental\* OR placenta\* OR abortion\* OR teratogenicit\* OR teratogeneit\* OR lactat\* OR lactic\* OR eclamp\* OR preeclamp\* OR pre-eclamp\* OR embryo OR embryopath\* OR fecundit\* OR sperm-ovum\* OR fertilit\* OR pregnant\* OR pregnanc\* OR feto OR fetomaternal\* OR fetus\* OR foetus\* OR fetal OR fetalmaternal\* OR foetal\* OR childbear\* OR gestat\* OR gravid\* OR labor OR labour OR ((child\*) NEAR/2 (bear\*)) OR ((breast\* OR mamma\* OR milk\*) NEAR/2 (secret\* OR excret\* OR releas\*)))) AND ((transplant\* OR allograft\* OR allotransplant\* OR autograft\* OR autotransplant\* OR graft\* OR isograft\* OR isotransplant\* OR retransplant\* OR xenograft\* OR xenotransplant\* OR inplant OR implant OR homograft\* OR homotransplant\*)) NOT ((animal\* OR rat OR rats OR mouse OR mice OR murine OR dog OR dogs OR canine OR cat OR cats OR feline OR rabbit OR cow OR cows OR bovine OR rodent\* OR sheep OR ovine OR pig OR swine OR porcine OR veterinar\* OR chick\* OR zebrafish\* OR baboon\* OR nonhuman\* OR primate\* OR cattle\* OR goose OR geese OR duck OR macaque\* OR avian\* OR bird\* OR fish\*) NOT (human\* OR patient\* OR women OR woman OR men OR man))) AND DT=(Article OR Review) AND LA=(English)('tacrolimus'/de OR 'mycophenolic acid'/de OR 'mycophenolate mofetil'/de

Google Scholar:

tacrolimus|prograft|"mycophenolic acid"|myfortic stillbirth|birth|abortion|teratogenicity|teratogeneity|lactation|fertility|pregnant|pregnancy|gestation|gravidity transplant|allograft|allotransplant|autograft|autotransplant|graft|xenograft|xenotransplant|homograft|homotransplant

**Supplemental Digital Content 2.**

|  |
| --- |
| **Table S2.** Incidence of low birth weight and prematurity in pregnancy after transplantation. |
| **Article, year** | **Pregnancy (n)** | **Organ transplantation** | **Drug** | **Livebirths** | **Birth weight (g)** | **LBW** | **Gestation (weeks)** | **Prematurity** | **Small for gestational age** |
| Kainz *et al.*, 2000 6 | 100 | Liver, kidney, heart, pancreas, lung | Tac | 68% | 2573 | N.A. | 35 | 59% | 10% |
| Armenti *et al.*, 2000 83 | 23 | Liver | Tac |  | 3021 | 17% | 37.4 | 33% |  |
| Carr *et al.,* 2000 84 | 6 | Liver | 50% Tac |  | 1727 | 67% | 33 | 50% |  |
| Nagy *et al.*, 2003 85 | 24 | Liver | Tac / CsA |  | 2762 | N.A. | 36.4 | 29.2% |  |
| Jain *et al.*, 2003 4 | 49 | Liver | Tac | 98.0% | 2797 | 22% | 36.4 | 46.9% | 8.5% |
| Armenti *et al.,* 2005 79 | 70 | Kidney | Tac | 71% | 2378 | 50% | 35 | 53% |  |
| Jabiry-Zieniewicz *et al.*, 2007 86 | 21 | Liver | 71% Tac |  | 2725 | 27% | 37.0 | 38% |  |
| Kubo *et al.*, 2014 87 | 38 | Liver | 71.1% Tac | 81.6% | N.A. | 38.7% | N.A. | 32.2% |  |
| Westbrook *et al.*, 2015 78 | 81 | Liver | Tac | 68% |  | 25% |  | 29% |  |
| Kanzaki *et al.*, 2016 75 | 26 | Liver | 81% Tac | 50% | 2858 | 31% | 38 | 23% | 23% |
| Dagher *et al.*, 2018 88 | 18 | Heart | 78% Tac | 72.2% | 2418 | 46.2% | 35.1 | 53.8% |  |
| Jain *et al*., 20045 | 22 | Kidney, kidney-pancreas | Tac | 95.5% | 2373 | 28,6% (<2000 gr) | 34.4 | 45.5% | 28.6% (<25th percentile) |
| Yuksel *et al*, 2019 89 | 26 | Kidney | Tac | 100% | 2215 | 57.7% | 33.6 | 73.1% |  |
| Aktürk *et al*. 2015 48 | 16 | Kidney | Tac | 68.7% | 2540 | 45.5% |  | 36.4% |  |
| Akarsu *et al*. 2016 77 | 21 | Liver | Tac | 100% | 2993 | 18.9% | 37.09 | 23.8% |  |
|  |  |  |  |  |  |  |  |  |  |
| Jain *et al*., 1997 47 | 27 | Liver | Tac | N.A. | 2638 |  | 36.6 | 52% | 20% (<10th percentile) |
| Mohamed-Ahmed *et al*. 2014 90 | 76 | LiverHeart, lung | 76% Tac | 91% | 26982364 | 37%54% | 35.5 | 42%54% | 16-21%8-23% |
| Kennedy *et al*, 2012 36 | 29 | Kidney | Tac | 79.3% | 3000 | 56.5% | 36.2 | 34% |  |
| Garcia-Donaire *et al.,* 2005 91 | 19 | Kidney | Tac |  |  |  |  |  | 10% |
| Al-Otaibi *et al*, 2019 92 | 33 | Kidney | Tac | 90.6 |  |  |  | 6.1% |  |
| Coscia *et al*., 2014 80 | 3852005652 | KidneyLiverPancreas- kidneyHeart | TacTacTacTac | 71%72.7%66%67% | 2489275721832570 | 43%30%58%36% | 35.436.13436.2 | 53%43%73%47% |  |
| Christopher *et al*. 2006 73 | 43 | Liver | Tac | 67.4% | 2660 | 31% | 37.5 |  |  |
| Dinelli *et al*., 2017 93 | 26 | Kidney | 72% Tac |  | 2630 |  | 36.9 | 51.9% | 40.7% |
| D’Souza *et al*., 2018 74 | 17 | Heart | 88% Tac | 81% | 2495 |  | 35 | 46.2% | 15.4% |
| Armenti *et al*., 2000 83 | 18 | Liver | Tac | 78.2% | 2617 | 43% | 37.4 | 43% |  |
| Jabiry-Zieniewicz *et al*., 2005 94 | 11 | Liver | 72.3% Tac | 100% | 2629 |  | 36.5 | 45.5% |  |
| Kamarajah *et al*., 2018 95  | 74 | Liver | Tac | 65% |  |  |  | 57% |  |
| Madej *et al.*, 2016 96 | 101 | LiverKidney | 76.8% Tac46.6% Tac |  | 32442429 |  | 36.635.4 | 42.8%71.1% |  |
| Miller *et al.*, 2000 97 | 8 | Liver | 50% Tac | 85.7% | 2010 | 50% | 29.1 |  |  |
| Perales-Puchalt *et al.*, 2012 98 | 9 | Kidney | Tac | 100% | 2800 | N.A. | 37.3 | 33.3% | 11.1% |
| Costa *et al.*, 2011 9 | 4 | Liver | Tac | 100% | 2721 | 50% | 36.9 | 25% | N.A. |
| Songin *et al.*, 2014 99 | 4348 | 21 Kidney38 Liver | TacTac | -1 | 22492899 |  | 34.736.8 | 74.4%43.8% |  |
| Ecevit *et al.*, 2012 100 | 4 | Liver | 75% Tac | 100% | 2285 | 100% | 34.5 | 75% | N.A. |
| Kim *et al*., 2015 50 | 28 | Kidney | Tac |  | 2493 | 42.9% | 35.8 | 53.6% | N.A. |
| Jabiry-Zieniewi *et al*., 2011 82 | 39 | Liver | 74.4% Tac |  | 2877 | 20% | 37.2 | 30.8% |  |
| Abbreviations: N.A., not applicable; LBW, low birth weight; Tac, tacrolimus; CsA, ciclosporin |

**Supplemental Digital Content 3.**

|  |
| --- |
| **Table S3.** Case reports: pregnancy outcomes in women on MPA treatment |
| **Article, year** | **n** | **Medication during pregnancy** | **MPA indication** | **Newborn** | **Birth defects** | **Additional information** |
| Kylat *et al*., 2017 133 | 1 | MMF 1000 mg 2/d (0 – 4 months)MMF 500 mg 2/d (4 months – 29 weeks)Prednisone 10 mg/d, Hydroxychloroquine 200 mg/dLow-molecular-weight heparin 65 mg 2/dAspirin mg 81 /d | SLE | Male29 weeks1295 g | Tricuspid regurgitationRight ventricular hypertrophy Patent ductus arteriosusAtrial septal defectTAPVR  |  |
| Lin *et al*., 2011 134 | 1 | MMF 1000 mg/day (0- 3 months)Prednisone 5 mg/dTacrolimus 6 mg/dOmeprazole 20 mg/d, Ferrous sulphate 600 mg/d | KTx | Male40 weeks2064 g  | Bilateral microtia Absent external auditory meatusEnlarged fontanelleBilateral microphthalmiaMicrognathiaModerate ankylosis of the jawCleft of the hard and soft palateDouble outlet right ventricleMitral atresiaPulmonic stenosisTAPVR |  |
| Parisi *et al*., 2008 135 | 1 | MMF 250 mg 2/dTacrolimus 5 mg/dPrednisone 5 mg/d NorvascMetoprololLasix EpogenAcyclovir (0 – 1st month)  | Lupus nephritis | Female35 weeks2136 g | Congenital diaphragmatic herniaMicrotiaEsophageal atresiaTracheoesophageal fistulaCleft palateCongenital heart defectDigital anomaliesDysmorphic facial features  |  |
| Ang *et al*., 2008 136 | 1 | 1st pregnancy:MMF 500 mg 3/d (week 0- 5)2nd pregnancy:MMF 4000 mg (for 4 days in week 7) | Recurrent erythema multiforme | -Female40 weeks2900 g | Bilateral microtia Absent external ear canals Unilateral inferonasal iris Chorioretinal coloboma  | Miscarriage after week 7 |
| Alsebayel *et al*., 2018 137 | 1 | 1st, 2nd, 3rd pregnancyMMFPrednisolone 5mg/dTacrolimus Lamivudine4th pregnancyMMF (week 0 - 20) | Ltx | Male38 weeks- | -Tracheoesophageal fistulaEsophageal atresiaBilateral ear canal atresia (microtia) | 3 miscarriagesWeek 6Week 6Week 9 |
| Perez-Aytes *et al*., 2008 138 | 1 | MMF 500 mg/day (stopped at 10 weeks)Tac 12 mg/day | Ktx | Female 41 weeks3050 g | Cleft lip and palateBilateral microtia Atretic external auditory canalsChorioretinal colobomaHypertelorismMicrognathia |  |
| Perales-Puchalt *et al*., 2012 98 | 1 | MMF | Ktx | - | Cleft palateBilateral microtiaExternal auditory conduct atresiaMicrognathiaHypertelorism Coloboma |  |
| Anderka *et al*, 2009 139 | 1 | MMF 1000 mg 2/d (discontinued at 12 weeks)PrednisoneLisinopril (discontinuedHydroxychloroquine (discontinued)Oral ironPrenatal vitaminsCalciumVitamin DAcetaminophen  | SLE | Male31 weeks980 g | Bilateral microtiaExternal auditory conduct atresiaTethered foreskinLeft hydroceleBilateral inguinal herniaSacral dimple |  |
| Jackson *et al*., 2009 140 | 1 | MMF 1000 mg 2/d (week 0-17)MMF 500 mg 2/d (week 17-35)Tac 5 mg 2/dPrednisone 2.5 mg 2/dPrenatal vitaminsFolic acidBactrim 800 mf 2/d (week 17-27)Acyclovir 400 mf 2/d (week 17-27) | Ltx | Female35 weeks- | Bilateral cleft lip and palateDouble-outlet right ventricle Mitral stenosisAnterior and rightward aorta Mild valvular pulmonary stenosisModerate hypoplasia left ventricleCataractsLeft microphthalmia Ocular hypertelorism MicrotiaExternal ear canal atresia Intestinal malrotationOverlapping fingers Segmental anomalies of the T2–T5 vertebral bodies, fusion of the 4th and 5th ribs on the right and 3rd, 4th, and 5th ribs on the left. |  |
| Sifontis *et al*., 2006 130 | 4 | MMF 1000 mg 2/d (week 0-26)MMF 500 mg 2/d (week 26 -34)TacPrednisoneMMF 500 mg 2/d (week 0-24)Sirolimus (week 24-31)TacPrednisoneCorticosteroids + thymoglobulin (week 24)MMF 250 mg 2/dTacPrednisoneMMF 1000 mg 2/d (0 - 2nd trimester)TacPrednisone | KtxKtxKtxKtx | -34 weeks2440 g-31 weeks1531 g-35 weeks2155 g-39 weeks2886 g | Hypoplastic nailsShortened fifth fingersCleft lip and palateMicrotiaCleft lip and palateMicrotiaCongenital diaphragmatic herniaCongenital heart defectsMicrotia | Died 1 day after delivery |
| Schoner *et al*., 2008 141 | 1 | MMF 750 mg 2/d (week 0-8)AZA (week 8 – 17)Cyclophosphamide | SLE | FemaleTermination at 17 weeks | Facial cleftsBilateral transverse mouth cleftMacrostomia Bilateral oblique cleftsShort noseHypoplasticRudimentary premaxilla ColobomasMicroretrognathiarudimentary auriclesAtretic auditory canalsHypoplastic thymus and lungsSubaortic ventricular septal defectOverriding common truncus arteriosus Esophageal atresiaTracheo-esophageal fistulaAberrant right subclavianSingle umbilical arteryLeft renal agenesisIpsilateral streak gonadMild hydrocephaly Agenesis of the corpus callosum |  |
| Pérgola *et al*., 2001 142 | 1 | MMF 1000 mg 2/d (day 0- 100)MMF 500 mg 2/d (day > 100)Prednisone 25 mg/dTacrolimus 7 mg 2/dCefepimeVancomycinNifedipine 30 mg/dTrimethoprim NystatinMultivitamin tabletsAcyclovir 800 mg 3/dFamotidine 20 mg 2/d | Ktx | Female2250 g | Hypoplastic nailsShortened fifth fingers | 2 healthy children using prednisone, cyclosporine, and azathioprine |
| Martín *et al*., 2014 143 | 4 | MMF 1000 mgTacrolimusMeprednisoneErythropoietin DiltiazemEnalaprilAmlodipineMMF (until week 8)MethylprednisoneEnoxaparinMMF (until week 8)AzathioprineHydroxychloroquinePrednisoloneCalciumMMF (until week 6)CyclosporineMeprednisoneAzathioprine (week 14- delivery)Usodeoxycholic acid (week 28 – delivery) Cholestyramine (week 28 – delivery)Diphenhydramine  | KtxSLESLEKtx | Female35 weeks1550 gFemale36 weeks2180 gFemale37 weeks2370 gmale35 weeks1610 g | Dysplastic ears with absent antihelixType I esophageal atresiaPatent foramen ovaleMicrophthalmiaRight upper eyelid colobomaBilateral microtiaRetrognathiaComplete bilateral cleft lip and palateDorsal hemivertebraeType III esophageal atresiaAtrioventricular canalPatent ductus arteriosusComplete unilateral cleft lip and palateBilateral microtiaAbsent left external ear canalOcular hypertelorismBilateral coloboma of irisChoroid and retinaEsophageal atresiaLumbar vertebral anomaliesPatent ductus arteriosusType III esophageal atresiaDorsal hemivertebrae | Child died 3 days after deliveryChild died 4 days after deliveryChild died 2 days after delivery |
| Le Ray *et al*., 2004 144 | 1 | MMF 500 mg/d(switch to Azathioprine 50 mg/d after week 13)Tacrolimus 9 mg/d Prednisone 15 mg/d | Ktx | -22 weeks- | Left cleft lip and palateMicrognathiaOcular hypertelorism Microtia External auditory duct atresia Left pelvic ectopic kidneyMidline anomalies including complete agenesis of the corpus callosum | Terminated after 22 weeks |
| Koshy *et al*., 2010 145 | 1 | MMF 250 mg 2/dTacrolimus 2 mg 2/dCyclosporine A 175 mg 2/dPrednisolone 5 mg Labetolol 200 mg 2/d | Ktx | Male32 weeks | Microtia Bilateral atresia of auditory canalsMild facial dysmorphism Downslanted palpebral fissuresNarrow jaw with mild retrognathia Bifid uvula |  |
| Hoeltzenbein *et al*., 2012 131 | 7 | MMF 750 mg/day (week 0-8)PrednisoneAzathioprineEnalaprilHydroxychloroquineAlendronateacetylsalicylic acidMMF 500 mg/day (week 0-41)PrednisoneTacrolimusAcebutololMMF 500 mg/day (week 0-10)EscitalopramLorazepamZolpidemMMF (week 0-8 + 26-36)PrednisoneTacrolimusAzathioprineFosfomycin (wk 14)MMF 1000 mg (week 0-18)PrednisoneCyclosporineUrsodeoxycholic acidMMF 1440 mg/day (week 0-5)AbataceptNaproxenPrednisolonecolchicine valaciclovirMMF (week 0-8)Prednisone, azathioprine, methyldopa | SLEKtxSLEKtxLtxHyper IgD syndrome | Male---41 weeks-Female35 weeks-31 weeks-36 weeks--36 weeks- | Microtia EACAColobomal cystOlfactory nerve agenesisHypertelorismMalar hypoplasiaBrachycephalyMicroretrognathiaesophageal atresia type IIIretroesophageal right subclavian arteryCampto‐/clinodactylia MicrotiaExternal Auditory Canal Atresiabenign cyst right kidneyTracheo‐esophageal atresia type 3Hydronephrosis AutismASD IIAsymmetry of brain ventriclesOccipital meningoceledysplastic left cerebellar hemisphereEACA | Pregnancy terminated at 26 weeks |
| Dei Malatesta *et al*., 2009 146 | 1 | MMF 500mg/dayTac 4 mg/dayPrednisone 5 mg every other day | KTx | Male 37 weeks2850 g | Unilateral coloboma |  |
| Andrade Vila *et al*., 2008 147 | 1 | MMF 500 mg/BID(after 5 weeks 250mg/BID)Tacrolimus 3 mg/BIDPrednisone 5mg/dayPravastatin 40mg/dayDiltiazem 60 mg/TIDcarbamazepine | Htx | --- | Left eye microphthalmiaComplete atresia of the auditory conduit and middle ear bilaterallyPalatine gap Bad formation of auricular pavilionUmbilical herniaPulmonary valve stenosis 15 mmHg |  |
| Huang *et al*., 2008 151 | 1 | MMF 1000mg 2dd (week 0-12)PrednisoloneHydroxychloroquine | SLE | Female22 weeks- | MicrognathiaOcular hypertelorismBilateral microtia External auditory duct atresiaNasal bifid anomaly | Pregnancy terminated at 22 weeks |
| Tjeertes *et al*., 2007 148 | 1 | MMF (week 0-20)PrednisoloneDarbepoetin alfaMethyldopa | KTx | male35 weeks2330 g | Ear malformationNon-immune hydrops fetalis | Fetal anemia |
| Velinov and Zellers *et al*., 2008 152  | 1 | MMF 500 mg 2dd (week 0-8)Adalimumab 40 mg | Lupus nephritis | Female32 weeks4422 g | HypertelorismEpicanthal foldsArching eyebrowsThick everted lower lipBilateral microtia with aural atresiaCleft palateCongenital tracheomalaciaBrachydactylyDevelopmental delay |  |
| El Sebaaly *et al*., 2007 153  | 1 | MMF 1000 mg bid (week 0-25)PrednisoneHydroxychloroquineperindopril | Lupus nephritis |  | Bilateral anotiaExternal auditory duct atresiaPolydactylyNail hypoplasia Kidney asymmetry Anterior positioning of the aortaInterventricular communication | Pregnancy was terminated |
| Ruiz-Campillo *et al*., 2008 154 | 1 | MMF 1500 mg/day (whole pregnancy)Deflazacort 90 mg/day | SLE with severe lupus nephritis | Female31 weeks1035 g | Cleft palateMicroretrognathia |  |
| Källén *et al*., 2005 149 | 1 | MMF (early pregnancy)TacPrednisoloneUrsodeoxycholic acid | LTx | --- | Esophageal atresiaComplex cardiac defectIris anomaly |  |
| Zahra *et al*., 2009 150 | 2 | MMF 1000mg (week 0-12)Cyclosporine 200mg (week 0-12)Cyclosporine 300mg (week 12-38)MMFCyclosporine 200mgPrednisolone 5 mg | LTxLTx | Female38 weeks2480 gMale38 weeks3100 g | -- |  |
| Abbreviations: MMF, mycophenolate mofetil; Tac, tacrolimus; SLE, systemic lupus erythematosus; KTx, kidney transplantation; LTx, liver transplantation; HTx, heart transplantation; TAPVR, total anomalous pulmonary venous returnTable adapted from Perez-Aytes138, Merlob156, and Anderka139. |